Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers

Journal of Proteomics

Volumn 73, Issue 6, 2010, Pages 1117-1132

  Ottervald, Jan ^a,b   Franzén, Bo ^b   Nilsson, Kerstin ^b   Andersson, Lars I ^b   Khademi, Mohsen ^a   Eriksson, Bodil ^b   Kjellström, Sven ^c   Marko Varga, György ^c,d   Végvári, Ákos ^d   Harris, Robert A ^a   Laurell, Thomas ^d   Miliotis, Tasso ^c   Matusevicius, Darius ^b   Salter, Hugh ^b,e   Ferm, Mats ^b   Olsson, Tomas ^a  

^a Center for Molecular Medicine   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

Biomarkers; CSF; Multiple sclerosis; Prognosis; Proteomics; Treatment

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 2 MACROGLOBULIN; ANGIOTENSINOGEN; BIOLOGICAL MARKER; CONTACTIN; COPPER ZINC SUPEROXIDE DISMUTASE; FETUIN A; FIBULIN; NATALIZUMAB; NERVE CELL ADHESION MOLECULE; NERVE CELL ADHESION MOLECULE 1; PROTEIN CONTACTIN 1; PROTEIN FIBULIN 1; PROTEIN NRCAM; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; FEMALE; FUNCTIONAL PROTEOMICS; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; BIOLOGICAL MODEL; CEREBROSPINAL FLUID; INFLAMMATION; METABOLISM; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PILOT STUDY; PROCEDURES; PROTEOMICS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; CEREBROSPINAL FLUID; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PILOT PROJECTS; PROTEOMICS;

EID: 77950597049     PISSN: 18743919     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jprot.2010.01.004     Document Type: Article

References (53)

1. Garcia Merino A., and Blasco M.R. Confirming the MS diagnosis. Int MS J 14 2 (2007) 58-63
2. McDonald W.I., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50 1 (2001) 121-127
3. Vladic A., et al. Cerebrospinal fluid and serum protein levels of tumour necrosis factor-alpha (TNF-alpha) interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R gp80) in multiple sclerosis patients. Cytokine 20 2 (2002) 86-89
4. Adam P., et al. CSF and serum orosomucoid (alpha-1-acid glycoprotein) in patients with multiple sclerosis: a comparison among particular subgroups of MS patients. Clin Chim Acta 334 1-2 (2003) 107-110
5. Teunissen C.E., Dijkstra C., and Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 4 1 (2005) 32-41
6. Norgren N., et al. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 63 9 (2004) 1586-1590
7. Miller D., et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 4 5 (2005) 281-288
8. Leary S.M., Porter B., and Thompson A.J. Multiple sclerosis: diagnosis and the management of acute relapses. Postgrad Med J 81 955 (2005) 302-308
9. Ray S., et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13 11 (2007) 1359-1362
10. Schulze-Topphoff U., et al. Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat Med 15 7 (2009) 788-793
11. Han M.H., et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 451 7182 (2008) 1076-1081
12. Dumont D., et al. Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. Proteomics 4 7 (2004) 2117-2124
13. Finehout E.J., Franck Z., and Lee K.H. Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis Markers 21 2 (2005) 93-101
14. Zerr I., et al. Diagnosis of Creutzfeldt-Jakob disease by two-dimensional gel electrophoresis of cerebrospinal fluid. Lancet 348 9031 (1996) 846-849
15. Dupont N.C., et al. Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants. J Reprod Immunol 66 2 (2005) 175-191
16. Miller D.H., et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348 1 (2003) 15-23
17. Polman C.H., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354 9 (2006) 899-910
18. Gonzalez H., et al. Identification of novel candidate protein biomarkers for the post-polio syndrome - implications for diagnosis, neurodegeneration and neuroinflammation. J Proteomics 71 6 (2009) 670-681
19. Wallman L., et al. Autonomous protein sample processing on-chip using solid-phase microextraction, capillary force pumping, and microdispensing. Electrophoresis 25 21-22 (2004) 3778-3787
20. Wold S., Sjöström M., and Eriksson L. PLS-regression: a basic tool of chemometrics. Chemometr Intell Lab Syst 58 2 (2001) 109-130
21. Mevik B.-H., and Wehrens R. The pls package: principal component and partial least squares regression in R. J Stat Softw 18 2 (2007)
22. Platten M., et al. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc Natl Acad Sci U S A (2009)
23. Stegbauer J., et al. Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc Natl Acad Sci U S A (2009)
24. Constantinescu C.S., et al. Serum angiotensin-converting enzyme in multiple sclerosis. Arch Neurol 54 8 (1997) 1012-1015
25. Wosik K., et al. Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis. J Neurosci 27 34 (2007) 9032-9042
26. Inaba S., et al. Continuous activation of renin-angiotensin system impairs cognitive function in renin/angiotensinogen transgenic mice. Hypertension 53 2 (2009) 356-362
27. Yuan X., and Desiderio D.M. Proteomics analysis of phosphotyrosyl-proteins in human lumbar cerebrospinal fluid. J Proteome Res 2 5 (2003) 476-487
28. Ohsawa I., Takamura C., and Kohsaka S. Fibulin-1 binds the amino-terminal head of beta-amyloid precursor protein and modulates its physiological function. J Neurochem 76 5 (2001) 1411-1420
29. Mattsson N., et al. Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. Mult Scler 15 4 (2009) 448-454
30. Benvegnu S., et al. Prion protein paralog doppel protein interacts with alpha-2-macroglobulin: a plausible mechanism for doppel-mediated neurodegeneration. PLoS One 4 6 (2009) e5968
31. Kanoh Y., et al. Serum matrix metalloproteinase-2 levels indicate blood-CSF barrier damage in patients with infectious meningitis. Inflammation 31 2 (2008) 99-104
32. Tchetverikov I., et al. Leflunomide and methotrexate reduce levels of activated matrix metalloproteinases in complexes with alpha2 macroglobulin in serum of rheumatoid arthritis patients. Ann Rheum Dis 67 1 (2008) 128-130
33. Tchetverikov I., et al. MMP protein and activity levels in synovial fluid from patients with joint injury, inflammatory arthritis, and osteoarthritis. Ann Rheum Dis 64 5 (2005) 694-698
34. Fernandes K.S., et al. Matrix metalloproteinase-9 genotypes and haplotypes are associated with multiple sclerosis and with the degree of disability of the disease. J Neuroimmunol (2009)
35. Mirowska-Guzel D., et al. Association of MMP1, MMP3, MMP9, and MMP12 polymorphisms with risk and clinical course of multiple sclerosis in a Polish population. J Neuroimmunol (2009)
36. Bernal F., et al. Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients. Mult Scler 15 6 (2009) 721-727
37. Mucke L., et al. Astroglial expression of human alpha(1)-antichymotrypsin enhances Alzheimer-like pathology in amyloid protein precursor transgenic mice. Am J Pathol 157 6 (2000) 2003-2010
38. Licastro F., et al. Increased levels of alpha-1-antichymotrypsin in brains of patients with Alzheimer's disease correlate with activated astrocytes and are affected by APOE 4 genotype. J Neuroimmunol 88 1-2 (1998) 105-110
39. Pasternack J.M., et al. Astrocytes in Alzheimer's disease gray matter express alpha 1-antichymotrypsin mRNA. Am J Pathol 135 5 (1989) 827-834
40. Padmanabhan J., et al. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons. Brain 129 Pt 11 (2006) 3020-3034
41. Nielsen H.M., et al. Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology 69 16 (2007) 1569-1579
42. DeKosky S.T., et al. Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment. Ann Neurol 53 1 (2003) 81-90
43. Correale J., Ysrraelit M.C., and Gaitan M.I. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain (2009)
44. Smolders J., et al. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 14 9 (2008) 1220-1224
45. Schafer C., et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112 3 (2003) 357-366
46. Gangneux C., et al. The inflammation-induced down-regulation of plasma fetuin-A (alpha2HS-glycoprotein) in liver results from the loss of interaction between long C/EBP isoforms at two neighbouring binding sites. Nucleic Acids Res 31 20 (2003) 5957-5970
47. Sato H., et al. Decreased levels of circulating alpha2-Heremans-Schmid glycoprotein/fetuin-A (AHSG) in patients with rheumatoid arthritis. Intern Med 46 20 (2007) 1685-1691
48. Tumani H., et al. CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis. Neurosci Lett 452 2 (2009) 214-217
49. Vucic S., and Kierna M.C. Pathophysiology of neurodegeneration in familial amyotrophic lateral sclerosis. Curr Mol Med 9 3 (2009) 255-272
50. Boll M.C., et al. Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochem Res 33 9 (2008) 1717-1723
51. Choi J., et al. Oxidative modifications and aggregation of Cu, Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J Biol Chem 280 12 (2005) 11648-11655
52. Brosnan C.F., and John G.R. Revisiting Notch in remyelination of multiple sclerosis lesions. J Clin Invest 119 1 (2009) 10-13
53. Khademi M., et al. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol 16 4 (2009) 528-536